Patent: 6,355,245

Summary for Patent: 6,355,245

Title:	C5-specific antibodies for the treatment of inflammatory diseases
Abstract:	The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.
Inventor(s):	Evans; Mark J. (Cheshire, CT), Matis; Louis A. (Southport, CT), Mueller; Eileen Elliott (East Haven, CT), Nye; Steven H. (Mequon, WI), Rollins; Scott (Monroe, CT), Rother; Russell P. (Cheshire, CT), Springhorn; Jeremy P. (Cheshire, CT), Squinto; Stephen P. (Bethany, CT), Thomas; Thomas C. (Madison, CT), Wilkins; James A. (Woodbridge, CT)
Assignee:	Alexion Pharmaceuticals, Inc. (Cheshire, CT)
Application Number:	08/487,283
Patent Claims:	see list of patent claims

Patent 6,355,245: Claims, Critical Validity Review, and US Landscape for Anti-C5 Alpha-Chain, C5a-Nonbinding Complement Blockade

United States Patent 6,355,245 claims antibodies and related compositions that (i) bind the alpha chain of human complement component C5, (ii) inhibit complement activation in human body fluid, (iii) block C5-driven hemolysis and C5a generation, and (iv) do not specifically bind free C5a. The patent also pins activity to dose-to-efficacy thresholds, binding-function ratios, and specific antibody identity elements for “Antibody 5G1.1 scFv CB (humanized)” encoded by specified sequences and nucleic acids, plus a deposited hybridoma (ATCC HB-11625).

Below is a critical claim-by-claim analysis, where each element is mapped to potential infringement, enforceability risk, and landscape pressure from known anti-C5 mechanisms and C5-targeting competitors.

---

What do the asserted claim elements actually cover?

Core claim architecture

Independent coverage is built around an antibody with five tightly coupled functional requirements:

1. Target binding location: antibody specific binding is “targeted to the alpha chain of human complement component C5” (Claim 1).
2. Complement functional blockade in human fluid: inhibits complement activation in “a human body fluid” (Claim 1).
3. Prevents formation of downstream C5 pathways: inhibits C5 binding to either C3 or C4 (Claim 1).
4. Avoids C5a binding: does not specifically bind free C5a (Claim 1).
5. Operational translation to assays/dosage: multiple dependent claims quantify inhibition (C5a generation and hemolytic activity) and specify dose/infusion thresholds (Claims 2, 6, 9, 10, 12, 13).

Claim 23 provides an alternative independent anchor on two functional readouts in human serum:

• inhibits “C5b-9-mediated hemolysis” and “C5a generation”
• does not specifically bind free C5a (Claim 23).

What is “alpha chain” coverage doing legally?

“Alpha chain of C5” limits the epitope to a particular structural region of C5 (Claim 1, Claim 19, Claim 23). That matters because many later anti-C5 antibodies bind C5 in ways that inhibit cleavage, but binding epitope selection can differentiate whether a competitor is captured by “alpha chain” language, depending on what is proven structurally in a given case.

---

Are the claims novel enough to survive a validity challenge?

Claim-by-claim critical points (novelty and obviousness exposure)

The most validity-sensitive elements are those that are both (i) narrow enough to be non-obvious and (ii) testable enough that examiners and challengers can compare against prior art.

Claim 1 (main antibody method-of-function definition)

Claim 1 binds the alpha chain of C5 and requires:

• complement activation inhibition in human body fluid
• inhibition of C5 binding to C3 or C4
• no specific binding to free C5a

Novelty pressure vectors

• General anti-C5 approach is known: Before and around the period when this patent likely emerged, C5 blockade was a known therapeutic mechanism (complement-mediated hemolysis and terminal complement). A validity attack usually argues that epitope selection and functional readouts would be routine in light of known complement biology.
• But the “no C5a binding” requirement is a constraint: Many anti-C5 agents prevent formation of C5a by blocking cleavage but may still bind C5a fragments depending on epitope. A challenger can argue this is a standard consequence of choosing an anti-C5 epitope unrelated to C5a, or it is an obvious engineering target.
• “Inhibits binding of purified human C5 to C3 or C4” is a mechanistic outlier: The language is not the standard “inhibit C5 cleavage” framing. A novelty attack can argue the C5 to C3/C4 interaction is not the canonical complement cascade step and that the assay may capture indirect inhibition rather than a true epitope-specific mechanism.

Enforceability exposure

• The clause “inhibits the binding of purified human C5 to either C3 or C4” can become a litigation focal point: if the competitor’s antibody does not measurably reduce those binding interactions in purified systems, non-infringement is plausible even if the competitor blocks complement in vivo.

Claim 2 and Claim 6 (assay equivalence and near-complete blockade)

• Claim 2: increments of blockade of C5a generation and blockade of complement hemolytic activity are “substantially equal.”
• Claim 6: “substantially complete blockade” of both endpoints when added at a ratio where antibody binding sites to C5 is ≤ 10:1.
• Claim 12: similar but ratio ≤ 3:1.

Validity pressure

• Quantitative thresholds often come under obviousness scrutiny: if prior art shows dose-response curves or equivalently effective blockade at similar ranges, the specific “substantially complete” and ratio cutoffs can be argued as result-determinative optimization.

Infringement pressure

• Competitor antibodies may achieve C5a and hemolysis inhibition but might not reproduce the “substantially complete” and ratio-dependent equivalence. These claims can be strong if the patent’s assays are well characterized, but they can also become difficult to enforce consistently across labs.

Claim 3 and Claim 4 (60% to 90% reduction binding of C5 to C3/C4)

• Claim 3: 60% to 90% reduction in ability of C5 to bind C3.
• Claim 4: 60% to 90% reduction in ability of C5 to bind C4.

Validity pressure

• A challenger can argue these ranges are arbitrary and cover expected effects from antibodies that alter C5 conformation or block interactions.
• If prior art already reports a reduction in C5 binding to C3/C4 with antibodies, these could be anticipated.

Infringement pressure

• Competitors can avoid these claim limitations if their mechanism does not yield the same binding reduction in the specific purified binding assay.

Claim 5 (epitope sequence window)

• Antibody binds an isolated oligopeptide corresponding to amino acids 8 through 12 of SEQ ID NO:1.

This is a meaningful narrowing feature. If competitors bind other C5 alpha-chain regions, they likely avoid literal infringement. However, doctrine-of-equivalents arguments are still possible if epitope similarity is demonstrated.

Claim 7 (humanized)

• “The antibody is a humanized antibody.”

This is a general category and usually has less discriminatory power.

Claim 8 (scFv)

• “The antibody is an scFv.”

This further constrains format. Many competitors use full-length IgG. scFv constructs can be engineered to bind C5 differently while still blocking complement. Literal coverage here is format-limited.

Claims 9, 10, 13 (intravenous infusion dose thresholds)

• Claim 9: “complete complement inhibition” at doses < 0.005 g/kg.
• Claim 10: “therapeutic benefits” at doses < 0.0022 g/kg.
• Claim 13: “therapeutically effective complement inhibition” at doses < 0.003 g/kg.

Critical vulnerability Dose thresholds are often the first target in validity challenges because:

• they depend on assay context (species model vs clinical serum levels, infusion schedule, endpoints, sampling times)
• they can be argued as non-novel optimization if prior art provides similar efficacy within the same order of magnitude

Litigation risk These claims can become hard to enforce if the patent does not lock endpoints and methods precisely enough for a court to compare across different experimental designs.

Claim 11 (extracorporeal circulation)

• Administered with extracorporeal circulation.

This is a narrower use/context. It can strengthen clinical relevance, but also limits infringement if competitors do not use the specific administration context.

Claim 14-17 (sterile non-pyrogenic and formulation; heterodimeric subunits)

• Claim 14: sterile non-pyrogenic therapeutic agent formulation.
• Claim 15: humanized immunoglobulin.
• Claim 16: scFv.
• Claim 17: two or more heterodimeric subunits each containing one heavy and one light chain.

These claims generally track standard biologics claim practice. The real competitive boundary is the underlying antibody definition of Claim 1 and the disclosed identity (Claims 18-22).

Claim 18-22 (identity claims tied to 5G1.1)

• Claim 18: “Antibody 5G1.1 scFv CB (humanized)” with amino acid sequence encoded by SEQ ID NO:8.
• Claim 19: isolated antigen binding protein with defined CDR sequences derived from SEQ ID NO:8.
• Claim 20: nucleic acid encoding variable heavy region amino acids 1-122 of SEQ ID NO:12.
• Claim 21: Hybridoma 5G1.1 with ATCC HB-11625.
• Claim 22: antibody produced by the hybridoma.

These are the most defensible for enforceability because they map to concrete sequences and a specific deposit. Competitors must either (i) avoid using that hybridoma/sequence, or (ii) show differences beyond what the claims cover.

Claim 23 (alternate independent functional set)

• Inhibits “C5b-9-mediated hemolysis” and “C5a generation” in serum.
• Does not bind free C5a.

This claim is strong because it uses widely recognized functional endpoints (terminal pathway hemolysis and C5a generation). It also relaxes the purified C5-to-C3/C4 binding language present in Claim 1, which increases the risk of capture of broader classes of anti-C5 antibodies that block cleavage but do not bind free C5a.

---

How broad are these claims versus known anti-C5 modalities in the US?

Mechanism mapping: what this patent is claiming relative to common anti-C5 approaches

All asserted claims converge on a blockade that prevents:

• hemolysis mediated by the terminal pathway (C5b-9)
• C5a generation (C5 cleavage products)

The most market-relevant implication: the patent is aimed at antibodies that stop the C5 cleavage step without binding free C5a.

Strategic breadth question

• Broadest coverage: Claim 23 plus Claim 1’s functional blockade could capture many anti-C5 antibodies that block cleavage and do not bind C5a.
• Narrowest coverage: Claim 18-22 and Claim 5 narrow to a specific humanized scFv sequence and a specific epitope window.

This means the practical enforceability is likely highest around sequence-defined embodiments (5G1.1) and around antibodies that bind the alpha chain and avoid C5a binding. Broad “functional” infringement becomes a fact-intensive exercise.

---

What is the critical patent landscape risk: existing and later anti-C5 patents?

This patent’s claim set is tightly focused on structural targeting of C5 (alpha chain) and absence of C5a binding, which is a differentiator. Still, the US competitive landscape for anti-complement C5 therapies includes multiple proprietary families, typically differentiating by:

• target epitope on C5
• whether C5a binding is present
• antibody format (IgG vs scFv or fragments)
• clinical indication set (PNH, aHUS, complement-mediated disorders, and sometimes extracorporeal contexts)

Business implication: The most credible enforcement path is sequence/epitope-defined embodiments (Claims 5, 18-20, 19’s CDR framework, and Claims 21-22). Functional-only coverage (Claims 1-4, 6, 12, 23) can still be asserted, but it invites harder infringement disputes because competitors can test cleavage and binding outcomes differently.

---

Where are the strongest infringement anchors for a competitor?

Most likely to capture competing antibodies

1. Alpha-chain targeted C5 binding
   • Claim 1 and Claim 19 require alpha chain targeting.
2. No specific binding to free C5a
   • Claim 1 and Claim 23 create a specific avoidance feature that could distinguish between C5-cleavage blockers and C5a-neutralizing agents.
3. Serum functional inhibition of C5a generation and C5b-9 hemolysis
   • Claim 23 is an enforceable functional profile.

Most likely to avoid infringement

1. Different C5 epitope outside the alpha chain
   • Claim 5’s oligopeptide window (AA 8-12 of SEQ ID NO:1) can be a hard stop.
2. Different antibody format
   • scFv-related limitations (Claim 8, Claim 16, Claim 18) do not cover full-length IgG unless other claims apply.
3. Failure to match quantified in vitro ratios/dose thresholds
   • Claims 6, 12, 9, 10, 13 are likely dependent on assay specifics and could be avoided by demonstrating different experimental performance or lower binding-site ratios needed to achieve the same endpoints.

---

What claims are most likely to be attacked for clarity and definiteness?

The claim language is generally coherent, but the following parts can create litigation pressure:

1. “Does not specifically bind”
   • This is definitional but depends on what binding assay, concentration, and threshold define “specific” binding.
2. “Substantially complete blockade”
   • Requires a quantitative standard in the record.
3. “Substantially equal” increments
   • Again depends on assay definition.

Those points do not typically destroy enforceability, but they increase evidentiary burden and can encourage settlement pressure.

---

How does the hybridoma deposit change enforcement posture?

Claim 21 identifies Hybridoma 5G1.1 with ATCC HB-11625 and Claim 22 covers antibodies produced by that hybridoma. This often improves enforcement because it ties the legal subject matter to an identifiable biological source. If an accused product is traceable to that hybridoma, infringement is more direct.

---

Landscape conclusion: what matters for R&D, licensing, and investment decisions?

• If a competitor product is a C5-cleavage blocker that does not bind free C5a, it is in the functional zone of Claim 23.
• If the competitor product binds C5 alpha chain and avoids C5a binding, it is in the structural zone of Claims 1 and 19.
• If the competitor avoids the specific sequence-derived embodiment (Claims 18-20 and the CDR mappings in Claim 19), the case strength shifts from literal sequence infringement to functional assay infringement.

In practice, business risk concentrates on whether a product matches:

• the epitope/sequence-defined embodiments (strongest), or
• the functional profile in human serum (harder but still actionable).

---

Key Takeaways

• US 6,355,245 covers anti-C5 antibodies that bind the alpha chain of human C5, block C5a generation and C5b-9 hemolysis, and do not specifically bind free C5a (Claims 1, 23).
• The patent’s strongest enforceability sits in identity-defined embodiments: the 5G1.1 scFv humanized sequence (SEQ ID NO:8), defined CDRs (Claim 19), nucleic acid for the variable heavy region (Claim 20), and the ATCC HB-11625 hybridoma (Claims 21-22).
• The most litigation-heavy coverage sits in functional and quantitative thresholds: “substantially complete” blockade, binding-site ratios (≤10 or ≤3), and IV infusion dose limits (<0.005 g/kg, <0.003 g/kg, and “therapeutic benefits” <0.0022 g/kg) (Claims 6, 9, 10, 12, 13).
• Competitive design-around is plausible by changing C5 epitope, binding to C5a fragments, or assay-measured binding reduction to C3/C4 that is explicitly required in Claims 1, 3, and 4.

---

FAQs

1) What is the single most important functional limitation in these claims?
Blocking C5a generation while also preventing C5b-9-mediated hemolysis, paired with no specific binding to free C5a (Claim 23; also Claim 1).

2) Does the patent require the antibody to be an scFv?
No. scFv is required only in dependent claims like Claim 8. The independent functional and alpha-chain coverage (Claim 1 and Claim 23) is not limited to scFv.

3) How do the ratio-to-C5 claims affect infringement risk?
Claims 6 and 12 require “substantially complete blockade” at specific moles of antibody-antigen binding sites to 1 mole C5 (≤10 or ≤3). A competitor can reduce risk by demonstrating that its product does not meet those thresholds under the same assay conditions.

4) What is the role of the ATCC HB-11625 deposit?
It anchors Claims 21-22 to a specific hybridoma source (“Hybridoma 5G1.1” and antibodies produced by it), improving enforceability against products derived from that source.

5) Which claims are most useful for a licensing discussion?
Claims that pin sequence/epitope identity (Claim 18-20 and Claim 19) plus the alpha-chain/C5a-nonbinding functional profile (Claim 1 and Claim 23). The quantitative dose and ratio claims (Claims 6, 9-10, 12-13) are negotiation points tied to performance evidence.

---

References

[1] United States Patent No. 6,355,245.

Details for Patent 6,355,245

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	March 16, 2007		2015-06-07

International Patent Family for US Patent 6,355,245

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9529697
United States of America	6074642
Portugal	758904
Netherlands	300433
Mexico	9605330